Connectome raises $2M to monitor brain health in real time
Zurich-based neurotechnology startup Connectome has secured a $2 million pre-seed round led by venture firm Redstone, backing its mission to continuously track brain health and detect cognitive decline long before symptoms become visible. The company claims its platform can identify up to 70% of silent cognitive changes that typically go unnoticed in everyday clinical practice.
A new model for continuous brain monitoring
Connectome is developing a non-invasive system that combines wearable sensors with advanced neuroimaging analytics and proprietary AI algorithms. Rather than relying on occasional memory tests or clinical visits, the startup aims to provide a continuous, data-driven view of how an individual’s brain function evolves over time.
By capturing subtle shifts in cognitive performance, reaction time, and neural activity, the platform is designed to spot early warning signs of neurodegenerative diseases such as Alzheimer’s and other forms of dementia. These changes often begin years before patients or families notice symptoms, limiting the window for effective intervention.
From reactive care to proactive prevention
The funding will be used to expand clinical validation, refine the company’s biomarker models, and build partnerships with hospitals, memory clinics, and pharmaceutical companies running clinical trials. By identifying high-risk individuals earlier, Connectome hopes to support more targeted therapies and personalized prevention plans.
Continuous brain tracking could also transform how new neurology treatments are evaluated. Objective, high-frequency data on cognitive change may help researchers detect drug effects faster, reduce trial costs, and better stratify patient populations.
Positioning Zurich as a neurotech hub
With strong ties to Switzerland’s academic and medical ecosystem, Connectome is part of a growing wave of European neurotech startups at the intersection of digital health, machine learning, and traditional neuroscience. The backing from Redstone signals rising investor confidence in technologies that can move healthcare from episodic check-ups to continuous, predictive monitoring.
As populations age and the burden of cognitive disorders grows, tools that can reliably track brain decline in daily life are likely to become a critical component of modern healthcare infrastructure.